Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)

Blood

Volumn 102, Issue 5, 2003, Pages 1622-1625

  Gatto, Simona ^b   Ball, Greg ^b   Onida, Francesco ^b   Kantarjian, Hagop M ^b   Estey, Elihu H ^b   Beran, Miloslav ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN;

ADULT; ARTICLE; CANCER SURVIVAL; FEMALE; HUMAN; KARYOTYPE; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; UNITED STATES;

EID: 0041941503     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-10-3264     Document Type: Article

References (21)

1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89: 2079-2088.
2. Schardijn GH, Statius van Eps LW. Beta 2-microglobulin: its significance in the evaluation of renal function. Kidney Int. 1987;32:635-641.
3. Gatto S, Onida F, Estey E, et al. Prognostic significance of serum beta-2-microglobulin levels in myelodysplastic syndromes [abstract 606]. Hematology J. 2002;3(suppl 1):182.
4. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
5. Beran M, Shen Y, Kantarjian H, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome. Cancer. 2001;92:1999-2015.
6. Thall PF, Estey E. Graphical methods for evaluating covariate effects in the Cox model. In: Crowley J, ed. Handbook of Statistics in Clinical Oncology. New York, NY: Marcel Dekker; 2001:411-432.
7. Aviles A, Diaz-Maqueo JC, Rodriguez L, Garcia EL, Guzman R, Talavera A. Prognostic value of serum beta 2 microglobulin in primary gastric lymphoma. Hematol Oncol. 1991;9:115-121.
8. Johnson PW, Whelan J, Longhurst S, et al. Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas. Br J Cancer. 1993;67:792-797.
9. Aviles A, Zepeda G, Diaz-Maqueo JC, et al. Beta 2 microglobulin levels as an indicator of prognosis in diffuse large cell lymphoma. Leuk Lymphoma. 1992;7:135-138.
10. Litam P, Swan F, Cabanillas F, et al. Prognostic value of serum beta-2 microglobulin in low-grade lymphoma. Ann Intern Med. 1991;114:855-860.
11. Dimopoulos MA, Cabanillas F, Lee JJ, et al. Prognostic role of serum beta 2-microglobulin in Hodgkin's disease. J Clin Oncol. 1993;11:1108-1111.
12. Rodriguez J, Pugh WC, Romaguera JE, et al. Primary mediastinal large cell lymphoma is characterized by an inverted pattern of large tumoral mass and low beta 2 microglobulin levels in serum and frequently elevated levels of serum lactate dehydrogenase. Ann Oncol. 1994;5:847-849.
13. Kyle RA. Prognostic factors in multiple myeloma. Stem Cells. 1995;13:56-63.
14. Keating MJ, O'Brien S, Robertson L, Huh Y, Kantarjian H, Plunkett W. Chronic lymphocytic leukemia: correlation of response and survival. Leuk Lymphoma. 1993;11:167-175.
15. Molica S, Levato D, Cascavilla N, Levato L, Musto P. Clinico-prognostic implications of simultaneous increased serum levels of soluble CD23 and beta2-microglobulin in B-cell chronic lymphocytic leukemia. Eur J Haematol. 1999;62:117-122.
16. Rodriguez J, Cortes J, Talpaz M, et al. Serum beta-2 microglobulin levels are a significant prognostic factor in Philadelphia chromosome-positive chronic myelogenous leukemia. Clin Cancer Res. 2000;6:147-152.
17. Onida F, Kantarjian HM, Smith TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood. 2002;99:840-849.
18. Kantarjian HM, Smith T, Estey E, et al. Prognostic significance of elevated serum beta 2-microglobulin levels in adult acute lymphocytic leukemia. Am J Med. 1992;93:599-604.
19. Otten GR, Bikoff E, Ribaudo RK, Kozlowski S, Margulies DH, Germain RN. Peptide and beta 2-microglobulin regulation of cell surface MHC class I conformation and expression. J Immunol. 1992;148:3723-3732.
20. Bethea M, Forman DT. Beta 2-microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci. 1990;20:163-168.
21. Ploegh HL, Orr HT, Strominger JL. Major histocompatibility antigens: the human (HLA-A, -B, -C) and murine (H-2K, H-2D) class I molecules. Cell. 1981;24,287-299.